Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Max Planck Innovation Launches Early-Stage Fund

This article was originally published in Start Up

Executive Summary

Frustrated by the continued lack of early-stage VC funding for projects emerging from its laboratories, Max Planck Innovations GMBH is launching its own VC fund, DDC Ventures. The fund is just one component of an ambitious tech transfer initiative dubbed the "drug development center", which kicked off last year with the creation of a Lead Discovery Center in Dortmund, Germany.

You may also be interested in...

GSK/Pentraxin: Targeting SAP in Amyloidosis, and Maybe Alzheimer's Too

University College London spin-out Pentraxin's February 2009 tie-up with GlaxoSmithKline in amyloidosis showed GSK's willingness to invest in risky, early-stage research. Weeks later, Pentraxin announced promising clinical data with a related program in Alzheimer's, raising the possibility that this alliance may yet expand beyond a specialist niche.

Asset-Focused Funding

A handful of early-stage VCs think they can generate better returns building and selling individual products, rather than companies.

COVID-19 Pandemic Accelerates Shift Toward Virtual Trials

As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation. 

Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts